Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

(2020) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

(2020) Kimberly K. Scarsi et al.   DRUGS

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study

(2020) Edwin Hayes et al.   Open Forum Infectious Diseases

Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

(2019) Kristina M. Brooks et al.   PHARMACOTHERAPY

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

(2019) Michael Aboud et al.   LANCET INFECTIOUS DISEASES

Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database

(2019) Daniel J. Ruzicka et al.   BMC INFECTIOUS DISEASES

Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors

(2019) Li-Li Yang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Bictegravir

(2018) Vincenzo Spagnuolo et al.   Current Opinion in HIV and AIDS

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

(2018) Maureen Oliveira et al.   Retrovirology

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen

(2017) François Raffi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study

(2017) Laurent Cotte et al.   PLoS One

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

(2016) Manuel Tsiang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy

(2014) José L. Blanco et al.   AIDS

Durability of first antiretroviral treatment in HIV chronically infected patients: why change and what are the outcomes?

(2014) Patricia Moniz et al.   Journal of the International AIDS Society

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and N.America 2002–2009

(2012) Sophie Abgrall   AIDS

Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*

(2012) C Stephan et al.   HIV MEDICINE

A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people

(2010) David R Bangsberg et al.   AIDS

One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects

(2010) Franco Maggiolo   Patient Preference and Adherence

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

(2009) S. Min et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY